Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

Sponsor
Henan Cancer Hospital
Study ID
NCT07233720
Status
Recruiting
Apply to this trial

Conditions

  • Marginal Zone Lymphoma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Zanubrutinib — DRUG
    160mg twice daily continuous oral administration.
  • Rituximab — DRUG
    375mg/m2, Intravenous administration on day 1 of each 3-week cycle

Study Details

This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).

Key Dates

Start date
Nov 18, 2025
Status verified
Oct 2025
Primary completion
Jun 30, 2028
Completion
Jun 30, 2030

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Zanubrutinib Combined With Rituximab
    Induction treatment: Rituximab, 375mg/m2, Intravenous administration on day 1 (21 days/cycle); Zanubrutinib, 160mg twice daily continuous oral administration from 1 to 8 cycles (21 days/cycle) Maintenance treatment: Zanubrutinib, 160mg twice daily continuous oral administration for two years (28 days/cycle)

Primary Outcome Measure

complete response rate [ Time Frame: every 6 weeks from the day of the first cycle of induction chemotherapy treatment (each cycle is 21 days) and every 8 weeks from the day of the first cycle of maintenance treatment (each cycle is 28 days) to 18 months after last patient's enrollment ]

Central Contacts

Related Studies